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A B S T R A C TObjectives: Pigmented skin lesions are commonly presented in pri-
mary care. Appropriate diagnosis and management is challenging
because the vast majority are benign. The MoleMate system is a
handheld SIAscopy scanner integrated with a primary care diagnostic
algorithm aimed at improving the management of pigmented skin
lesions in primary care. Methods: This decision-model–based eco-
nomic evaluation draws on the results of a randomized controlled trial
of the MoleMate system versus best practice (ISRCTN79932379) to
estimate the expected long-term cost and health gain of diagnosis
with the MoleMate system versus best practice in an English primary
care setting. The model combines trial results with data from the wider
literature to inform long-term prognosis, health state utilities, and cost.
Results: Results are reported as mean and incremental cost and quality-
adjusted life-years (QALYs) gained, incremental cost-effectiveness ratio
with probabilistic sensitivity analysis, and value of information analysis.
Over a lifetime horizon, the MoleMate system is expected to cost an extrasee front matter Copyright & 2013, International
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ondence to: Edward C.F. Wilson, Health Economics£18 over best practice alone, and yield an extra 0.01 QALYs per patient
examined. The incremental cost-effectiveness ratio is £1,896 per QALY
gained, with a 66.1% probability of being below £30,000 per QALY gained.
The expected value of perfect information is £43.1 million. Conclusions:
Given typical thresholds in the United Kingdom (£20,000–£30,000 per
QALY), the MoleMate system may be cost-effective compared with best
practice diagnosis alone in a primary care setting. However, there is
considerable decision uncertainty, driven particularly by the sensitivity
and specificity of MoleMate versus best practice, and the risk of disease
progression in undiagnosed melanoma; future research should focus on
reducing uncertainty in these parameters.
Keywords: cost-effectiveness, diagnosis, malignant melanoma,
primary care, value of information.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Pigmented skin lesions (moles) are a common reason for patients
presenting in primary care. The vast majority of moles are
benign, and, in the United Kingdom, only 5% to 12% of those
referred via the urgent referral route to specialist care are
diagnosed as malignant melanoma [1,2]. The incidence of malig-
nant melanoma worldwide continues to rise, doubling every 10 to
20 years [3]. In the United Kingdom, in 2008, there were 11,770incident cases diagnosed and 2070 deaths from melanoma [4].
Prognosis is predicted by tumor thickness at diagnosis [5],
making early detection and treatment critical in improving
survival rates.
There is conflicting evidence concerning general practitioner
(GP) diagnosis of melanoma. While GPs appear to be as sensitive
as dermatologists at diagnosing melanoma, they may be less
specific, thus accounting for the high false-positive rate observed
in referred patients [6]. Because of the severe consequences forSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 5 6 – 3 6 6 357the patient, GPs are naturally concerned not to overlook any
potentially malignant lesions. Overreferral, however, has impli-
cations not only for the patients themselves in terms of anxiety
but also for other patients as the opportunity cost of the referral
is unnecessary delays to other patients.
The MoleMate system is a novel diagnostic aid comprising a
handheld SIAscopy scanner incorporating an algorithm developed
for use in primary care [7]. SIAscopy is a noninvasive scanning
technique that produces images of hemoglobin, melanin, and
collagen in the epidermis and papillary dermis: it has been shown
to improve diagnostic accuracy in secondary care settings [8,9].
The MoleMate UK Trial (ISRCTN79932379) [10,11], set in
English general practice, aimed to determine whether the use
of the MoleMate system in primary care would result in more
appropriate referrals of suspicious pigmented lesions to special-
ist care compared with current best practice alone (as recom-
mended by the National Institute for Health and Clinical
Excellence [NICE] [12]: clinical history, naked eye examination,
and seven-point checklist). This economic evaluation, comprising
a decision model drawing on key data collected in the random-
ized controlled trial (RCT) as well as other relevant literature,
aims to establish the cost-effectiveness of the system plus best
practice compared with best practice alone in a primary care
setting in England from the perspective of the National Health
Service.Methods
We developed a decision model comprising a decision tree with
Markov chains at the terminal nodes drawing primarily on the
results of an RCT of the MoleMate system. Full details and results
of the trial are reported elsewhere [10,11]. Briefly, the trial was a
pragmatic RCT enrolling 1293 participants in 15 general practices
in the East of England. Participants were aged 18 years or older
having at least one suspicious pigmented lesion, defined as any
lesion presented by a patient, or opportunistically detected by a
GP or practice nurse, that could not immediately be diagnosed as
benign. Participants were randomized to comparison (best prac-
tice) or intervention (MoleMate) groups. The comparison group
had their lesion(s) assessed by a lead clinician according to NICE
guidelines [12], including clinical history, naked eye examination,
and completion of the seven-point checklist [13,14]. The lead
clinician then decided to either refer or reassure the patient. The
intervention group followed the same protocol with the addition
of the MoleMate system. All patients who were not referred were
offered a follow-up with the lead clinician 3 to 6 months later to
confirm the benign diagnosis.
The primary outcome from the trial was the appropriateness
of referral defined as the proportion of referred lesions that
secondary care experts decided to biopsy or monitor; it was a
measure of the diagnostic accuracy of the GP with or without the
aid of the MoleMate system, and represented the positive pre-
dictive value. The lead clinician’s diagnostic performance, namely,
the proportion of benign lesions appropriately managed in pri-
mary care (negative predictive value), the percentage agreement
with the expert decision to biopsy/monitor (sensitivity), and the
percentage agreement with the expert assessment that the lesion
was benign (specificity), was assessed by using data from all
lesions in the trial (histology result or expert clinical diagnosis).
These sensitivity and specificity estimates and prevalence of
‘‘suspicious lesions’’ were used as primary inputs into a decision
model to estimate the expected long-term cost and quality-
adjusted life-years (QALYs) gained from using the MoleMate
system plus best practice compared with best practice alone
(see Table 1 and Appendix 2.1 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2012.12.008).Model Structure
A decision tree was developed to estimate the expected cost and
outcomes associated with using and not using the MoleMate
system in the primary care setting to aid the decision to either
refer the patient or reassure (Figure 1). Markov chains (labeled M1,
M2, and M3) at each terminal node were used to estimate long-term
costs and outcomes following the initial contact with the health
service (Fig. 2A–C). The model begins with patients presenting
with a mole that is defined to be either ‘‘clinically significant’’
(i.e., needing specialist referral) or ‘‘not clinically significant’’
according to a reference standard diagnosis [10,11] (i.e. Dþ or D,
but it is unknown which the patient has at this point; Figure 1). The
clinician can choose either to refer (Tþ) or to not refer (T). This
will either be a true positive or negative (Tþ9Dþ or T9D, i.e., a
correct decision) or false positive or negative (Tþ9D or T9Dþ,
i.e., an incorrect decision). The probabilities of a true positive or
negative are the sensitivity and specificity of the management
decision, respectively. The three Markov chains estimate the
expected cost and outcomes following detection of a true positive
(M1), a false negative (M2), or a true negative or a false positive (M3).
The pathways in the comparison group (best practice alone) are
identical to those in the intervention (best practice plus MoleMate)
group. The transition period for the Markov chains is 1 year.
Histological diagnosis within the MoleMate Trial differenti-
ated between a number of types of benign and malignant skin
disease. For the purpose of the decision model, it was important
to estimate the (quality-adjusted) life expectancy and lifetime
cost of patients. Malignant skin disease comprises basal cell
carcinoma following which a normal life expectancy can be
assumed, squamous cell carcinoma, and malignant melanoma.
As the strongest predictor of prognosis is Breslow thickness and
stage at diagnosis [5] and to keep the model as simple and
transparent as possible, the model takes account only of disease
stage at diagnosis, and does not further differentiate between
melanoma or squamous cell carcinoma type.
Patients entering Markov chain M1 (true positives diagnosed
and treated; Figure 2A) enter the appropriate state corresponding
to disease status at diagnosis. They remain in that state (‘‘Hx.’’)
until death.
Markov chain M2 uses the same basic structure; however, these
patients have had a false-negative diagnosis. Therefore, they have
undiagnosed disease. Each year they have a probability of remain-
ing in the undiagnosed state, progressing and dying, or of being
opportunistically detected and treated. If detected and treated,
patients’ prognosis and costs are determined in the same manner
as for Markov chain M1. Figure 2B presents a stylized summary of
the model for clarity. The full structure is given in Appendix 1 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2012.12.008.
Patients entering Markov chain M3 do not have a clinically
significant lesion. Therefore, the Markov chain is trivial: their
costs are assumed to be zero and to follow normal life expectancy
(Figure 2C).
Model Inputs
The model was populated with data from the MoleMate Trial
[10,11] (including the sensitivity and specificity of the compara-
tors and the prevalence of suspicious lesions) and other relevant
literature [2,5,15–28] supplemented with expert opinion where
necessary (natural history of melanoma, survival, other transi-
tion probabilities, health state utilities, and costs).
Costs
Patients enter the model at their MoleMate Trial consultation.
Timing a random sample of consultations (n ¼ 32 intervention
Table 1 – Model inputs.
Parameter Mean SE/n Distribution Source
Trial data
All participants
Prevalence of suspicious moles 18.8% 1.1% b(236, 1020) MoleMate Trial
Sens of diagnosis with MM 98.4% 1.1% b(121, 2) MoleMate Trial
Spec of diagnosis with MM 82.1% 1.7% b(413, 90) MoleMate Trial
Sens of best practice diagnosis 95.6% 1.9% b(108, 5) MoleMate Trial
Spec of best practice diagnosis 89.2% 1.4% b(461, 56) MoleMate Trial
Log-odds ratio of death vs. 1a melanomay
1a 0 –
1b 1.449 0.083 N(1.449, 0.083) [5]
2a 2.506 0.082 N(2.506, 0.082) [5]
2b 3.045 0.083 N(3.045, 0.083) [5]
2c 3.731 0.091 N(3.731, 0.091) [5]
3a 2.626 0.101 N(2.626, 0.101) [5]
3b 3.486 0.092 N(3.486, 0.092) [5]
3c 4.215 0.105 N(4.215, 0.105) [5]
4 5.743 0.080 N(5.743, 0.080) [5]
Annual risk of progression of undiagnosed melanoma (stage x4 stage y)z
0 4 1A 5.00% 0.15 D(0.15, 0.15, 0.3, 2.4) Adapted from [16]
0 4 1B 5.00% 0.15 D(0.15, 0.15, 0.3, 2.4) Adapted from [16]
0 4 opportunistic detect 10.00% 0.30 D(0.15, 0.15, 0.3, 2.4) Adapted from [16]
0 4 0 80.00% 2.40 D(0.15, 0.15, 0.3, 2.4) Adapted from [16]
1A 4 1B 10.00% 0.30 D(0.3, 0.15, 0.15, 0.3, 2.1) Adapted from [16]
1A 4 2A 5.00% 0.15 D(0.3, 0.15, 0.15, 0.3, 2.1) Adapted from [16]
1A 4 2B 5.00% 0.15 D(0.3, 0.15, 0.15, 0.3, 2.1) Adapted from [16]
1A 4 opportunistic detect 10.00% 0.30 D(0.3, 0.15, 0.15, 0.3, 2.1) Adapted from [16]
1A 4 1A 70.00% 2.10 D(0.3, 0.15, 0.15, 0.3, 2.1) Adapted from [16]
1B 4 2B 5.00% 0.15 D(0.15, 0.15, 0.3, 2.4) Adapted from [16]
1B 4 2C 5.00% 0.15 D(0.15, 0.15, 0.3, 2.4) Adapted from [16]
1B 4 opportunistic detect 10.00% 0.30 D(0.15, 0.15, 0.3, 2.4) Adapted from [16]
1B 4 1B 80.00% 2.40 D(0.15, 0.15, 0.3, 2.4) Adapted from [16]
2A 4 2B 10.00% 0.30 Adapted from [16]
2A 4 3A 5.00% 0.15 D(0.3, 0.15, 0.15, 0.3, 2.1) Adapted from [16]
2A 4 3B 5.00% 0.15 D(0.3, 0.15, 0.15, 0.3, 2.1) Adapted from [16]
2A 4 opportunistic detect 10.00% 0.30 D(0.3, 0.15, 0.15, 0.3, 2.1) Adapted from [16]
2A 4 2A 70.00% 2.10 D(0.3, 0.15, 0.15, 0.3, 2.1) Adapted from [16]
2B 4 2C 10.00% 0.30 D(0.3, 0.15, 0.15, 0.3, 2.1) Adapted from [16]
2B 4 3B 5.00% 0.15 D(0.3, 0.15, 0.15, 0.3, 2.1) Adapted from [16]
2B 4 3C 5.00% 0.15 D(0.3, 0.15, 0.15, 0.3, 2.1) Adapted from [16]
2B 4 opportunistic detect 10.00% 0.30 D(0.3, 0.15, 0.15, 0.3, 2.1) Adapted from [16]
2B 4 2B 70.00% 2.10 D(0.3, 0.15, 0.15, 0.3, 2.1) Adapted from [16]
2C 4 3C 10.00% 0.30 D(0.3, 0.3, 2.4) Adapted from [16]
2C 4 opportunistic detect 10.00% 0.30 D(0.3, 0.3, 2.4) Adapted from [16]
2C 4 2C 80.00% 2.40 D(0.3, 0.3, 2.4) Adapted from [16]
3A 4 3B 10.00% 0.30 D(0.3, 0.3, 0.3, 2.1) Adapted from [16]
3A 4 4 10.00% 0.30 D(0.3, 0.3, 0.3, 2.1) Adapted from [16]
3A 4 opportunistic detect 10.00% 0.30 D(0.3, 0.3, 0.3, 2.1) Adapted from [16]
3A 4 3A 70.00% 2.10 D(0.3, 0.3, 0.3, 2.1) Adapted from [16]
3B 4 3C 10.00% 0.30 D(0.3, 0.3, 0.3, 2.1) Adapted from [16]
3B 4 4 10.00% 0.30 D(0.3, 0.3, 0.3, 2.1) Adapted from [16]
3B 4 opportunistic detect 10.00% 0.30 D(0.3, 0.3, 0.3, 2.1) Adapted from [16]
3B 4 3B 70.00% 2.10 D(0.3, 0.3, 0.3, 2.1) Adapted from [16]
3C 4 4 10.00% 0.30 D(0.3, 0.3, 2.4) Adapted from [16]
3C 4 opportunistic detect 10.00% 0.30 D(0.3, 0.3, 2.4) Adapted from [16]
3C 4 3C 80.00% 2.40 D(0.3, 0.3, 2.4) Adapted from [16]
4 4 opportunistic detect 10.00% 0.30 D(0.3, 2.7) Adapted from [16]
4 4 4 90.00% 2.70 D(0.3, 2.7) Adapted from [16]
Starting states (chains M1 and M2)
Stage 0 95.00% 615980 Dirichlet [2]
Stage 1A 1.46% 9452 Dirichlet [5]
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Table 1 (continued)
Parameter Mean SE/n Distribution Source
Stage 1B 1.38% 8918 Dirichlet [5]
Stage 2A 0.72% 4644 Dirichlet [5]
Stage 2B 0.50% 3228 Dirichlet [5]
Stage 2C 0.22% 1397 Dirichlet [5]
Stage 3A 0.18% 1196 Dirichlet [5]
Stage 3B 0.21% 1391 Dirichlet [5]
Stage 3C 0.11% 720 Dirichlet [5]
Stage 4 0.23% 1474 Dirichlet [5]
Utilities
No cancer 1.00 – Fixed Assumption
Stage 0 0.93 0.013 Normal [23]
Stage 1 0.93 0.013 Normal [23]
Stage 2 0.87 0.057 Normal [23]
Stage 3 0.89 0.046 Normal [23]
Stage 4 0.52 0.117 Normal [23]
Unit costs
GP consultation per minute £3.10 – Fixed [24]
MoleMate system scan £14.24 – Fixed Manufacturer
Initial referral £109.00 G(17.52, 6.22) [27]
Biopsy excision £132.00 G(5.90, 22.38) [27]
Definitive surgery £161.00 G(19.99, 8.05) [27]
CXR £26.65 G(7.20, 3.70) [27]
CT scan £151.00 G(10.54, 14.33) [27]
Liver function test £3.00 G(4.04, 0.74) [27]
FBC £3.00 G(4.04, 0.74) [27]
Sentinel node biopsy (pathology cost) £34.00 G(3.88, 8.76) [27]
Radical lymph node dissection £1024.00 G(2.50, 410.23) [27]
Surgical removal of localized metastases £835.00 G(2.14, 391.49) [27]
Radiotherapy (planning) £729.00 G(1.06, 689.05) [27]
Radiotherapy (per fraction) £111.00 G(10.93, 10.16) [27]
Chemotherapy (dacarbazine, procurement) £197.00 G(0.45, 439.40) [27]
Chemotherapy (dacarbazine, delivery first attendance) £231.00 G(2.65, 87.28) [27]
Chemotherapy (dacarbazine, delivery subsequent) £206.00 G(5.86, 35.13) [27]
Dermatology follow-up £56.00 G(52.94, 1.06) [27]
Summary costs (point estimates)
GP consultation, MoleMate £74.40
GP consultation, best practice £68.51
Chemotherapy, cycle £1458.00
Radiotherapy, 10 fraction cycle £1839.00
Year 1 Hx stage 0 £349.00
Year 1 Hx stages 1a, 1b £920.57
Year 1 Hx stage 2a £1146.47
Year 1 Hx stages 2b, 2c £1330.11
Year 1 Hx stages 3a–3c £2505.11
Year 1 Hx stage 4 £5462.11
Hx stage 0–4 £0.00
Last year of life Hx stages 0–1a £0.00
Last year of life Hx stage 1b–4 £4,132.00
Note. Distributions: b, beta; N, normal; D, Dirichlet; G, gamma.
CT, computed tomography; CXR, chest X-ray; FBC, full blood count; GP, general practitioner; Hx, history of (i.e. patient diagnosed with); MM,
malignant melanoma; Sens, sensitivity; Spec, specificity.
* Standard error of mean for beta and normal distributions, n for Dirichlet.
y Figures shown are log-odds and variance of log-odds. Stages defined as per Balch et al. [5].
z Probabilities sampled from Dirichlet distributions were subsequently adjusted for risk of death.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 5 6 – 3 6 6 359group, 30 comparison group) yielded a mean (standard error) time
of 24 (2.8) and 22.1 (3.2) minutes with and without the MoleMate
system, respectively. These were multiplied by a per-minute
consultation cost [24] to estimate the total cost of the diagnostic
consultation.The MoleMate system costs £2500 to purchase, with £250 per
year for technical support after the first year (source: manufac-
turer). Assuming a 5-year life, £2500 capital cost and £250 per-
annum maintenance, and 48 patients presenting per 10,000 per
year, we estimate a cost of £14.24 per scan (Appendix Table A2.3 in
MoleMate
Best Pracce
Clinically signiﬁcant mole (D+)
Not clinically signiﬁcant (D-)
Refer (T+|D+)
Not refer (T-|D+)
M1
M2
M3
M3
M1
M2
M3
M3
Clinically signiﬁcant mole (D+)
Not clinically signiﬁcant (D-)
Refer (T+|D-)
Not refer (T-|D-)
Refer (T+|D+)
Not refer (T-|D+)
Refer (T+|D-)
Not refer (T-|D-)
Fig. 1 – Decision tree structure.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 5 6 – 3 6 6360Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2012.12.008).
Patients who are referred to specialist care incur the cost of
an initial consultation (Table 1). False positives are then dis-
charged, incur no further costs, and are assumed to live a
normal lifespan. Treatment costs for true positives were based
on 2010 UK guidelines for the management of cutaneous
melanoma [25] comprising biopsy excision, staging [5], and
definitive surgery. Patients with stage 0, Ia, and Ib disease
undergo no further treatment. Patients with stage IIa and above
undergo sentinel lymph node biopsy. Patients with stage IIb and
above undergo chest X-ray, computed tomography scan, liver
function test, and full blood cell count. Patients with a positive
sentinel lymph node biopsy undergo follow-up surgery com-
prising preoperative computed tomography scan and radical
lymph node basin dissection. Patients with stage IV disease
undergo surgery for removal of localized metastases, a course
of 10 fractions of radiotherapy, and six cycles of dacarbazine-
based chemotherapy.
Patients with in-situ (stage 0) disease have only 1 follow-up
appointment. Patients with stage I disease are followed up every
3 months for 3 years before discharge (total 12 visits), and
patients with stage II followed up as per stage I, followed by
twice-yearly checks for a further 2 years (total 16 visits) [25]. For
ease of modeling, the discounted cost of all these visits was
added to the first-year cost.Terminal Care Costs
In the model, patients with stage 0 or Ia disease have a normal
lifespan. Patients with stage Ib disease and above have a reduced
life expectancy [5] and are therefore assumed to die as a result of
their disease. Previous studies of lifetime melanoma-related
costs of melanoma patients show peaks in resource consumption
at initial treatment and terminal phase for all patients, irrespec-
tive of stage at diagnosis [26]. Therefore, the costs in the final
year of life for patients with Ib disease and above are assumed
to be the same as for the treatment of metastatic disease
(surgical removal of localized metastases, radiotherapy, and
chemotherapy).
Undiagnosed Melanoma (False Negatives)
Patients with undiagnosed melanoma are assumed to not incur
any costs unless their disease is opportunistically detected (in
which case treatment costs are dependent on stage at diagnosis
as described above), or they die of their disease, in which case
terminal care costs are incurred as described above. The model
uses tunnel states to ensure that treatment and terminal
care costs are incurred at the appropriate time points (Appen-
dix 1 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2012.12.008).
Model inputs are reported in Table 1, and full details of
calculations are given in Appendix 2.
Alive Dead
Undiagnosed 
melanoma
Opportunistic 
detection and 
treatment
Dead
  
 
Hx  IA
Hx  IB
Hx  IIA
Hx  IIB
Hx  IIC
Hx  IIIA
Dead
Hx  IIIB
Hx  IIIC
Hx  IV
Hx  0
a
b
c
Fig. 2 – (A) Markov chain M1. Note that stage ‘‘0’’ includes benign lesions. (B) Stylized representation of Markov chain M2. See
Appendix 1 for the full model structure. (C) Markov chain M3.
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We defined the base-case analysis as a 45-year-old patient with
one potentially suspicious lesion. The price year and currency for
the analysis is GB£2011.The model estimates expected lifetime costs and QALYs
accrued; those incurred after the first year are discounted at the
standard recommended [29] UK rate of 3.5%; 5000 Monte Carlo
simulations calculated expected lifetime costs and QALYs gained
with the MoleMate system and best practice. Results are reported
Table 2 – Point estimate results.
Analysis Expected cost (£) Expected QALYs Inc. £ Inc. QALYs ICER (£) P(ICERo £30k) (%)
MoleMate Control MoleMate Control
Base (45 y) 1133 1115 15.108 15.098 18 0.01 1896 66.1
East of England 1812 1780 15.015 15.005 32 0.01 3172 76.5
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-years.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 5 6 – 3 6 6362as mean and incremental costs and QALYs, incremental cost-
effectiveness ratio (ICER; calculated as mean incremental costs
divided by mean incremental QALYs), scatter-plot of incremental
cost-QALY pairs, the cost-effectiveness acceptability curve, and
the probability that the ICER is below £30,000 [30]. One-way
sensitivity analyses were performed on key parameters. We also
calculated the expected values of perfect information and perfect
parameter information [31]. Population value of information
statistics are based on 296,600 patients presenting in primary
care, and a time horizon of 10 years (details in Appendix 2 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2012.12.008).
The base-case analysis combines data from the MoleMate
Trial with other relevant national and international data. We also
present an additional scenario analysis using trial data for the
prevalence of melanoma at diagnosis and East of England cancer
registry data [32] for stage at diagnosis (parameters reported in
Appendix 3), which may be more relevant for English data (the
MoleMate Trial setting).Results
We estimate diagnosis by using the MoleMate system to cost £18
more and yield 0.01 additional QALYs per patient (or £18,000 for
10 additional QALYs per 1000 patients) assessed compared with-£500
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Fig. 3 – Scatter plot of incremental cost and QALY pairs. The figu
the 5000 Monte Carlo samples. The dotted line represents a thr
each quadrant: NW 7.9%; NE 72.1%; SW 0.5%; SE 19.6%. NE, nor
southeast; SW, southwest.best practice over a lifetime horizon. The incremental cost per
QALY gained is therefore £1896. The analysis specific to the East
of England yields similar results to the base case (see Table 2).
Analysis of uncertainty shows a preponderance of model
iterations in the northeast quadrant of the cost-effectiveness
plane (Figure 3), suggesting that using the MoleMate system is
probably both more effective and more expensive than best
practice. At a typical willingness-to-pay value of £30,000 per
QALY gained, there is a 66.1% probability that the MoleMate
system is cost-effective compared with best practice (Figure 4).
One-way sensitivity analyses show that the results are insensi-
tive to estimates of the specificity of both MoleMate and best
practice and the time required for a consultation with the
MoleMate system but are sensitive to estimates of the sensitivity
of each intervention. The ICER is below £30,000 so long as the
price per scan is below £290. At current purchase and main-
tenance prices, this equates to two to three scans per annum.
Given a £30,000 valuation of a QALY, we estimate the expected
value of perfect information at £43.1 million (Figure 4). The expected
value of perfect parameter information is £32.2 million for the
sensitivity and specificity of the MoleMate system versus best
practice, and £13.5 million for the risk of progression in undiagnosed
and untreated disease. The expected value of perfect parameter
information for other model parameters (prevalence of moles, risk of
death, stage at diagnosis, health state utilities, and cost) is zero
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there is a 60.3% probability that the ICER is below £20,000 per QALY gained and 66.1% probability that it is below £30,000.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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Interpretation of Results
The best estimate of the ICER (£1896) is below conventional
thresholds of cost-effectiveness and suggests that the use of
the MoleMate system is likely to be cost-effective compared with
implementation of current best practice clinical assessment in
primary care, despite its association with more referrals for£0
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sens, sensitivity; spec, specificity; susp., suspected; w, with.specialist practice. This is because its use is expected to result
in fewer missed cases of melanoma in the community, with
consequent implications for patient outcomes and cost.
This analysis represents a synthesis of ‘‘all relevant evidence’’
[33], and its conclusions form a recommendation on the basis of
expected outcomes. It is axiomatic that decision makers should
be risk neutral and base their decisions on expected values alone
[31]. Risk averse decision makers, however, may wish to bear in
mind the substantial decision uncertainty this analysis has
revealed and may prefer to await further evidence beforesta
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 5 6 – 3 6 6364changing policy at this time: acceptance of the results is depend-
ent on the acceptance of the decision model as a sufficient
representation of reality. Furthermore, there may be costs asso-
ciated with reversing the decision at a later date [34].
Over a lifetime horizon, expected differences in cost and
QALYs gained per patient are small. This is because most
patients’ lesions are benign: a high QALY gain and/or cost to a
few patients are averaged over the entire population (Table 2).
The ICERs of between £1800 and £3200 per QALY gained are well
within the £20,000 to £30,000 threshold used by the National
Health Service and NICE, and therefore use of the MoleMate
system in primary care to help diagnose suspicious lesions in
addition to best practice may be considered a cost-effective use of
resources.
Of interest is the comparison between the results of this
economic evaluation and the trial report [11], which concluded
that the MoleMate system did not add to best practice application
of NICE guidelines in terms of appropriateness of referral: on
average, MoleMate had higher sensitivity (albeit not statistically
significant) and significantly lower specificity than best practice
alone [11], suggesting that on average it increases the number of
both appropriate and inappropriate referrals. This model trans-
lates the trade-off between increases in appropriate and in-
appropriate referrals into overall expected health gain and cost
of adding the MoleMate system to best practice, concluding that
the extra benefit is ‘‘worth’’ the extra cost, given National Health
Service thresholds.
This raises an interesting policy implication: conventional
thought (and a driver behind the design of the MoleMate trial
itself) is that there is room to reduce the number of specialist
referrals because many lesions are benign and therefore not in
need of specialist attention. These results suggest that both the
cost and health consequences of overreferring (because of lower
specificity of the MoleMate system vs. best practice alone) are
outweighed by the benefits of the additional cases detected that
would otherwise be missed (the higher sensitivity). This is
consistent with a recent study suggesting that European coun-
tries with strict gate-keeping mechanisms in primary care have
poorer 1-year overall cancer survival [35]. English primary care
may need to lower its threshold for referral of patients with
possible cancer, an approach that may be cost-effective but
analysis of which is beyond the scope of this analysis.
Analysis of Uncertainty
We estimated a 66.1% probability that the ICER is below £30,000.
This decision uncertainty translates into an expected value of
perfect information of £43.1 million. This is the expected value of
eliminating all decision uncertainty [31]. Of course, sample data
will never give perfect information, and so the value of such data
(the expected value of sample information) will be less than this.
As £43.1 million is likely to be above the cost of a ‘‘typical’’ data
collection exercise (e.g., RCT, epidemiological study, or database
analysis), more research into this decision problem may be
efficient (although the EVSI is required to confirm this). The
expected value of perfect parameter information indicates that
the greatest gains are in reducing uncertainty in sensitivity and
specificity estimates, and the risk of progression of an undiag-
nosed melanoma. There is no gain from reducing uncertainty in
the other model parameters.
Strengths and Weaknesses
This analysis draws on data from a rigorously conducted RCT set
in English primary care, combined with other relevant data
extracted systematically from appropriate sources. Economic
evaluations are often limited to within-trial analyses of costsand outcomes. However, the primary outcome of the trial was the
appropriateness of referral (positive predictive value of the
management decision, i.e., the probability that a patient who is
referred has a clinically significant mole i.e., [P(Dþ9Tþ)]). This
outcome is less useful for economic evaluation because making
decisions on the allocation of scarce resources requires a com-
mon outcome metric. Ultimately, we are interested in the change
in health gain and cost associated with implementing the
MoleMate system. The decision model provides a framework
for applying individual outcomes of the trial and, by combining
with other data, predicting their impact on overall health gain
expressed in QALYs, and cost [36].
This approach is consistent with the principles of evidence-
based medicine and good practice in decision modeling [33,37].
By their nature, however, the design of models is subject to a
number of compromises and simplifications, and the need to
draw on expert opinion and assumptions in the absence of
relevant data. The validity of the results and policy conclusions
rests on the plausibility and applicability of the model to a
particular setting. The major strength of this analysis is that it
lays out the assumptions (which would be implicitly required in
any case) in an open and transparent manner. The appendices
are written in a format to allow challenge and replication of
the model.
There are a number of assumptions and limitations of the
model. Cost-effectiveness, as an incremental analysis, is always a
relative concept; therefore the comparator is crucial. In the
MoleMate Trial the comparator was not ‘‘usual practice’’ but
‘‘best practice.’’ The cost-effectiveness of best practice compared
with usual practice is unknown, and therefore inferences as to
the cost-effectiveness of the MoleMate system compared with
current practice must be made with caution. The best practice
guidelines, however, are in accordance with the recommenda-
tions of NICE. If these were fully implemented, then this analysis
demonstrates that on average, addition of the MoleMate system
on top of these would be efficient.
A particular weakness in this model is the need for assump-
tions regarding the natural history of melanoma in undiagnosed
and hence untreated patients, and the likelihood of opportunistic
detection and treatment. A prospective cohort study to establish
this would clearly be unethical. A previous modeling study [16]
assumed a baseline probability of progression of 10% per annum,
justified on the basis of a clinical expert consensus. Because this
is a key area of uncertainty, a high variance was assigned to the
distribution of likely values in their sensitivity analysis. In this
analysis, we assigned the same values to the risk of progression.
The value of information analysis suggests that this is an area in
which future research would be beneficial. In the absence of
experimental data, a formal structured elicitation process [38]
may be useful in summarizing expert opinion.
A further limitation is the use of a reference standard to
define sensitivity and specificity rather than a ‘‘gold standard’’ of
biopsy. This issue is discussed in the outcomes article [11];
however, the decision model takes account of this aspect by
grouping all benign lesions into stage 0 disease, for which it is
assumed that patients follow a normal lifespan.
The model assumes that those patients who are falsely
reassured that their lesion is benign (false negatives) will not
re-present again for the same reason at a later date, other than
due to opportunistic detection (for which we assumed a 10%
probability per annum). If this is not a reasonable assumption,
the model will underestimate the cost of repeated scans with the
MoleMate system. Similarly though, any subsequent detection
may offset the higher cost of treating later stage disease, and will
result in better health outcomes than estimated. Thus, the
impact on cost-effectiveness is unclear and full consideration of
this aspect is beyond the scope of this model.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 5 6 – 3 6 6 365Generalizability
The applicability of these results to different settings depends on
how closely the assumed treatment pathways and epidemiology
of the disease match those of other settings.
In the model, the treatment pathways for melanoma at differ-
ent stages were based on a recent set of guidelines that at the time
of writing may not represent current practice in all settings [25].
Furthermore, we made use of US data on prognosis after
diagnosis, obtained from the largest prospective cohort study of
melanoma prognosis [5]. These data provide very precise esti-
mates of risk and are the basis for the staging system used
worldwide. Their generalizability, however, to the United
Kingdom is a matter of judgment because treatment patterns
(and hence outcomes and cost) vary between time and place.
We analyzed a scenario relevant to the East of England, using trial
data [11] for the prevalence of melanoma and regional cancer
registry data [32] for the distribution of stage at diagnosis. The
results were not substantially different from the base case (£3172
vs. £1896 per QALY gained; Table 2). One-way sensitivity analysis
on the cost per scan of the MoleMate system suggests that it
remains cost-effective as long as it is used at least three to four
times per year (equating to £190 per scan; Appendix 4 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2012.12.008).
Comparison with Other Studies
To our knowledge, this is the first economic evaluation of the use
of a diagnostic aid for the management of pigmented lesions in
primary or secondary care. Previous evaluations of primary care
diagnostic techniques focus on different screening approaches
and techniques to improve uptake in various disease areas [39–47].
We identified only one other economic study of an interven-
tion aimed at reducing inappropriate referrals: a primary care
algorithm to reduce unnecessary referrals for suspected deep
venous thrombosis in a Dutch setting reduced not only the
expected cost per patient (h138, 2006 euros) but also expected
QALYs (0.002). It was considered, however, cost-effective as the
foregone health gain was small compared with the cost savings
that can then be invested elsewhere to greater effect [48].Conclusions
There is little difference in expected cost or QALYs gained from
using the MoleMate system compared with best practice in
managing pigmented lesions in a primary care setting. The
incremental cost per QALY gained is approximately £1900, which
may be considered cost-effective given UK thresholds, but there
is considerable decision uncertainty. Additional research into
sensitivity and specificity estimates and into the risk of progres-
sion in undiagnosed disease may be beneficial and efficient. The
former could be achieved with a further RCT while the latter
could be based on elicitation of expert opinion.Acknowledgments
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